+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by Type and Geography - Global Forecast and Analysis 2019-2023 - Product Image

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by Type and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4833472
  • Report
  • Region: Global
  • 116 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • MORE
Global CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) Inhibitors Market: About this market

The CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis considers sales from both monotherapy and combination therapy . Our analysis also considers the sales of CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) inhibitors in Asia, Europe, North America, and ROW. In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low side effects due and better tolerability will play a significant role in the monotherapy segment to maintain its market position. Also, our global CTLA4 inhibitors market report looks at factors such as high target affinity and specificity of CTLA4 inhibitors, growing popularity of combination therapy, and strategic alliances. However, lack of approved therapies, availability of substitutes, and stringent regulations may hamper the growth of the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors industry over the forecast period.

Global CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) Inhibitors Market: Overview

High target affinity and specificity of CTLA4 inhibitors

CTLA4 inhibitors function by boosting the immune system and reducing the side effects. CTLA-4 is a protein found on the surface of T-cells which suppress the growth of cancer cells by activating the immune system. These drugs work directly on the target, and their efficacy is higher than that of other conventional treatments such as chemotherapy. Though the CTLA4 inhibitors are new to the oncology treatment landscape, increasing R&D efforts by market vendors are supporting the growth of CTLA4 inhibitors market This will lead to the expansion of the global CTLA4 inhibitors market at a CAGR of over 9% during the forecast period.

Increasing awareness about cancer

The awareness programs conducted by various organizations provide an opportunity to raise awareness about lung cancer screening and treatment options, including CTLA4 inhibitors. For instance, Cancer Breakthroughs 2020 an initiative taken by the US government for the development of research on vaccine-based immunotherapies for cancer. This project aimed at making therapies available to more patients while detecting the disease at an early stage. Such awareness programs are also raising awareness about the treatment of various cancer types by using CTLA4 inhibitors. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global CTLA4 inhibitors market is highly concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading CTLA4 inhibitors manufacturers, that include AstraZeneca Plc, Bristol-Myers Squibb Co., Ono Pharmaceutical Co. Ltd.

Also, the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Monotherapy - Market size and forecast 2018-2023
  • Combination therapy - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Expansion of research indications
  • Special drug designations
  • Increasing awareness about cancer
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Ono Pharmaceutical Co. Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: AstraZeneca Plc - Vendor overview
Exhibit 45: AstraZeneca Plc - Business segments
Exhibit 46: AstraZeneca Plc - Organizational developments
Exhibit 47: AstraZeneca Plc - Geographic focus
Exhibit 48: AstraZeneca Plc - Key offerings
Exhibit 49: AstraZeneca Plc - Key customers
Exhibit 50: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 51: Bristol-Myers Squibb Co. - Business segments
Exhibit 52: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 53: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 54: Bristol-Myers Squibb Co. - Key offerings
Exhibit 55: Bristol-Myers Squibb Co. - Key customers
Exhibit 56: Ono Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 57: Ono Pharmaceutical Co. Ltd. - Business segments
Exhibit 58: Ono Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 59: Ono Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 60: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibit 61: Ono Pharmaceutical Co. Ltd. - Key customers
Exhibit 62: Validation techniques employed for market sizing
Exhibit 63: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • MORE
The following companies are recognised as the key players in the global CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) inhibitors market: AstraZeneca Plc, Bristol-Myers Squibb Co., Ono Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing awareness about cancer.”

According to the report, one of the major drivers for this market is the high target affinity and specificity of CTLA4 inhibitors.

Further, the report states that one of the major factors hindering the growth of this market is the lack of approved therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Ono Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll